Imatinib Mesylate: A Time Tested Solution For Chronic Myeloid Leukemia (CML)

Abstract

Imatinib mesylate is a time tested solution for the chronic myeloid leukemic patients, it is a tyrosine kinase inhibitor which was approved from Federal Drug Agency FDA in 2001 and used in the initial phase of CML, and it can also be used in those patients who are not responding to interferon alpha-1 therapy in late stages. Imatinib mesylate has good (98%) bioavailability after oral administration. Studies showed that the drug contains mild adverse effects in animal models and was found to be suitable in all aspects for humans; however teratogenicity were also reported that is why it is not recommended for pregnant women.